(PRWEB) October 16, 2013
The Corporate Whistleblower Center says, "One of the easiest ways to cheat Medicare is to charge it for services that were never rendered, and or never needed." For example, recently a major pharmaceutical company was allegedly giving kickbacks to increase market share. Sadly, the Medicare patients did not need the medication. If a pharmaceutical insider has well documented proof of this type of wrongdoing, we'd like them to call us at 866-714-6466, so we can explain federal whistleblower programs to them and the types of proof needed to get rewarded."
This example is in reference to a recent settlement between Amgen Pharmaceuticals and the United States Department of Justice, in which Amgen agreed to pay a massive $24.9 million to settle allegations that they violated the False Claims Act. According to a press release from the Department of Justice, Amgen allegedly paid kickbacks to long-term care pharmacy providers in exchange for implementing programs that switched Medicare and Medicaid patients from a competitor drug to Aranesp, a drug made by Amgen. The lawsuit also alleged that Amgen used materials that encouraged pharmacists to use Aranesp for patients off-label. http://CorporateWhistleblowerCenter.Com
In this case, the whistleblower will receive a significant portion of the $24.9 million settlement.
Simple rules for a whistleblower from the Corporate Whistle Blower Center:
The Corporate Whistleblower Center wants to emphasize there are high quality whistleblowers in every state. Potential whistleblowers with proof of wrongdoing in excess of $1 million are encouraged to call the Corporate Whistleblower Center anytime at 866-714-6466, for more information about federal whistleblower reward programs. They can also contact the group via their web site: Http://CorporateWhistleBlowerCenter.Com
For attribution please refer to the USDOJ press release on this matter dated April 16th 2013:http://www.justice.gov/opa/pr/2013/April/13-civ-438.html
Case Number: The False Claims Act suit was filed in the U.S. District Court for the District of South Carolina, and is captioned United States ex rel. Kurnik v. Amgen Inc., et al.